Anadys to ponder selling the company in strategic review

Shares of Anadys Pharmaceuticals (NASDAQ: ANDS) jumped eight percent this morning after the hepatitis C drug developer announced that it plans a strategic review that could trigger a sale of the company. Another option for Anadys would be the sale or licensing of ANA598, a hep C drug now in mid-stage development. Lazard Freres & Co. LLC has been brought in as an adviser during the process. "The impressive safety and antiviral response data we recently released establish a very...

Anadys shares climb on upbeat PhII case for hep C drug

Shares of San Diego-based Anadys (NASDAQ: ANDS) got a pre-market bump this morning after the developer announced completed Phase II data for its hepatitis C drug ANA598 and sought to qualm fears about the high placebo response that had earlier spooked investors. Anadys zeroed in on the high rate of response for patients taking a 200-mg dose of the drug plus standard of care. A total of 73 percent of the patients in that cohort had no detectable levels of the virus after 12 weeks of treatment,...